Brief: PAION: FDA considers current human abuse liability program with remimazolam in U.S. as sufficient

PAION AG

14/11/2017 09:15

Nov 14 (Reuters) - PAION AG  PA8G.DE  
    * FDA CONSIDERS CURRENT HUMAN ABUSE LIABILITY PROGRAM WITH 
REMIMAZOLAM IN U.S. AS SUFFICIENT 
    * NO SECOND INTRANASAL STUDY REQUIRED 
    * ASSUMES CLINICAL DEVELOPMENT PROGRAM FOR REMIMAZOLAM IN 
PROCEDURAL SEDATION IN U.S. AS COMPLETED 
 
Source text for Eikon:  ID:nEQ33T7D1a  
Further company coverage:  PA8G.DE  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))